Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 300

1.

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG.

N Engl J Med. 2015 Aug 26. [Epub ahead of print]

PMID:
26308596
2.

Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma.

Prabhala RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A, Nanjappa P, Pai C, Lee S, Prabhala NS, Bandi RL, Smith R, Lazo-Kallanian SB, Valet S, Raje N, Gold JS, Richardson PG, Daley JF, Anderson KC, Ettenberg SA, Di Padova F, Munshi NC.

Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.228. [Epub ahead of print]

PMID:
26293646
3.

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.

Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP.

Leukemia. 2015 Jul 3. doi: 10.1038/leu.2015.164. [Epub ahead of print]

PMID:
26139427
4.

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC, Tonon G.

Cancer Discov. 2015 Jun 16. [Epub ahead of print]

PMID:
26080835
5.

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.

Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF.

Expert Rev Anticancer Ther. 2015 Jul;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7.

PMID:
26051506
6.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.

Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.

PMID:
26032514
7.

Promising therapies in multiple myeloma.

Bianchi G, Richardson PG, Anderson KC.

Blood. 2015 Jul 16;126(3):300-10. doi: 10.1182/blood-2015-03-575365. Epub 2015 Jun 1. No abstract available.

PMID:
26031917
8.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC.

Clin Cancer Res. 2015 May 15. [Epub ahead of print]

PMID:
25979485
9.

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.

Hideshima T, Cottini F, Ohguchi H, Jakubikova J, Gorgun G, Mimura N, Tai YT, Munshi NC, Richardson PG, Anderson KC.

Blood Cancer J. 2015 May 15;5:e312. doi: 10.1038/bcj.2015.38.

10.

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Mohty M, Richardson PG, McCarthy PL, Attal M.

Bone Marrow Transplant. 2015 Aug;50(8):1024-9. doi: 10.1038/bmt.2015.83. Epub 2015 Apr 20. Review.

PMID:
25893452
11.

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.

Laubach JP, Richardson PG.

Clin Cancer Res. 2015 Jun 15;21(12):2660-2. doi: 10.1158/1078-0432.CCR-14-3190. Epub 2015 Apr 15.

PMID:
25878332
12.

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.

Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9.

PMID:
25832873
13.

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.

Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ.

Br J Haematol. 2015 Jul;170(1):66-79. doi: 10.1111/bjh.13394. Epub 2015 Mar 30.

PMID:
25824111
14.

Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.

Kikuchi S, Suzuki R, Ohguchi H, Yoshida Y, Lu D, Cottini F, Jakubikova J, Bianchi G, Harada T, Gorgun G, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Leukemia. 2015 Mar 24. doi: 10.1038/leu.2015.83. [Epub ahead of print]

PMID:
25801913
15.

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT).

Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, Arat M, Bader P, Baron F, Bazarbachi A, Blaise D, Ciceri F, Corbacioglu S, Dalle JH, Duarte RF, Fukuda T, Huynh A, Masszi T, Michallet M, Nagler A, NiChonghaile M, Pagluica T, Peters C, Petersen FB, Richardson PG, Ruutu T, Savani BN, Wallhult E, Yakoub-Agha I, Carreras E.

Bone Marrow Transplant. 2015 Jun;50(6):781-9. doi: 10.1038/bmt.2015.52. Epub 2015 Mar 23.

16.

Resolving the daratumumab interference with blood compatibility testing.

Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, Doshi P, Kaufman RM.

Transfusion. 2015 Jun;55(6 Pt 2):1545-54. doi: 10.1111/trf.13069. Epub 2015 Mar 12.

PMID:
25764134
17.

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Richardson PG, Laubach JP, Munshi NC, Anderson KC.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):255-61. doi: 10.1182/asheducation-2014.1.255. Epub 2014 Nov 18.

PMID:
25696864
18.

Management of relapsed multiple myeloma after autologous stem cell transplant.

Holstein SA, Richardson PG, Laubach JP, McCarthy PL.

Biol Blood Marrow Transplant. 2015 May;21(5):793-8. doi: 10.1016/j.bbmt.2014.12.026. Epub 2015 Jan 31. Review.

PMID:
25652690
19.

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

Mateos MV, Richardson PG, Dimopoulos MA, Palumbo A, Anderson KC, Shi H, Elliott J, Dow E, van de Velde H, Niculescu L, San Miguel JF.

Am J Hematol. 2015 Apr;90(4):314-9. doi: 10.1002/ajh.23933. Epub 2015 Feb 27.

PMID:
25557740
20.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG.

Lancet Oncol. 2014 Dec;15(13):1503-12. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14.

PMID:
25456369
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk